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According to the 2011 World Health Organization Global Status 
Report, of the 57 million annual global deaths – a staggering 36 million or 
over 63% are due to chronic diseases.1 Four noncommunicable diseases - 
namely cardiovascular, cancer, diabetes, and chronic respiratory 
diseases - emerge as the leading cause of mortality in the world, 
accounting respectively for 17, 7.6, 4.2, and 1.3 million deaths based on 
the latest available global epidemiology data. By 2020, global deaths due 
to chronic diseases are projected to worsen by at least 15 to 20%. It is 
estimated that the four major noncommunicable diseases will be 
responsible for 75% of worldwide deaths by 2030.2 
 Progress to date on noncommunicable diseases has been vastly 
inadequate at global scale, resulting in a rampant pandemic. As 
described by the World Health Organization Director-General Margaret 
Chan, “The rise of chronic noncommunicable diseases presents an 
enormous challenge. For some countries, it is no exaggeration to describe 
the situation as an impending disaster; a disaster for health, for society…”.3  
 Alarmingly, across all continents (with the exception of Africa), 
deaths from noncommunicable diseases now exceed those from 
communicable, maternal, perinatal and nutritional conditions combined. 
For men in Europe, for example, deaths from noncommunicable diseases 
are 13 times higher than other causes combined, and for men in the 
Western Pacific region, they are 8 times higher. Remarkably, the burden of 
chronic diseases is rising disproportionately among lower income countries 
and populations, with nearly 80% of noncommunicable disease-
associated deaths reported in low- and middle-income countries.1-3 
 Chronic diseases are an under-appreciated cause of poverty that 
hinders the economic development around the world. The burden is 
growing - the number of people, families and communities afflicted is 
increasing. Noncommunicable diseases stand as a major barrier to 
achievement of the anti-poverty Millennium Development Goals, with 
urgent action required to integrate management of chronic diseases into 
global health priorities. 
 Tackling the global noncommunicable diseases crisis requires a 
concerted and coordinated multi-sectorial response, committed across 
societies at large. This requires adapting health systems and health 
policies, and a shift from disease-centered to people-centered 
approaches and population health measures. Vertical initiatives are 
insufficient to meet complex population needs, so integrated solutions 
that engage a matrix of disciplines and sectors are needed.1-3 
 Evidence-based and cost-effective interventions exist to prevent 
and control the threat of chronic diseases at global, regional, national 
and local levels. Modifiable risk factors, including tobacco, harmful use of 
alcohol, unhealthy diet, insufficient physical activity, obesity, as well as 
hypertension, hyperglycemia and hypercholesterolemia are recognized 
as major contributors to the underlying pathobiology of chronic disease 
processes.1-5 Comprehensive and integrated action at country/continent 
level is thus mandatory to advance solutions in order to prevent morbidity 
and disability. To this end, implementation of the World Health 
Organization Action Plan for the Global Strategy for the Prevention and 
Control of noncommunicable diseases, the Global Strategy on Diet, 
Physical Activity and Health, and the Global Strategy to Reduce the 
Harmful Use of Alcohol are all vital initiatives.1-3 
 Establishment of a United Nations 2012-2022 Decade of Action on 
Noncommunicable Diseases has been advocated to ensure that 85% of 
the world’s population has access to information, education and services 
to reduce vulnerability and death rates associated with chronic diseases. 
In this context, the Noncommunicable Diseases Alliance, steered by the 
International Diabetes Federation, the International Union against 
Tuberculosis and Lung Disease, the Union for International Cancer Control 
and the World Heart Federation, and representing over 900 professional 
member organizations in 170 countries, has been at the forefront of 
advocacy.6 Recommendations, at worldwide scale, include promotion of 
population-wide prevention, early detection, screening, and awareness-
raising programs for noncommunicable diseases targeting populations at 
risk. This would include by 2013, development and implementation of 
regulatory measures to achieve substantial reductions in levels of 
saturated fats, trans-fats, salt and refined sugars in processed foods, as 
well as to reduce worldwide salt intake.6 By 2018, the goal is to decrease 
mortality and morbidity of cardiovascular diseases, diabetes, as well as 
gastric, colorectal, breast, and cervical cancer by increasing early 
detection, implementing immunization strategies for human 
papillomavirus and hepatitis B virus for populations at high risk, and 
globally reducing environmental, occupational and contextual risk factors 
associated with noncommunicable diseases.6 Ensuring universal access to 
affordable, safe and effective, quality noncommunicable diseases 
diagnosis and treatment, and further strengthening of national and 
community-based health systems to enable continuity of care are indeed 
paramount. 
 Transforming community and global health would further require 
accelerated fundamental research to acquire new knowledge on 
disease causes and cures, integrated across an effective translational 
continuum of prevention, treatment and management for the spectrum 
of chronic disease conditions.7 Leveraging discovery to the benefit of 
patients and populations encompasses multiple integrated steps.8,9 By 
addressing a global unmet need, initial discovery science leads to 
development and evaluation of candidate health applications, followed 
by validation and prescription of evidence-based recommendations for 
clinical practice and health decision-making, and finally patient-centric 
translation which strives to disseminate health care interventions integral 
to community practices.8-12 Advancing the medical model of 
‘intervention’ into the public health model of disease management or 
‘prevention’ ultimately enables prevention and behavioral alterations in 
communities and populations.8,9 The public health model focuses on 
information and education programs that eliminate deleterious behaviors 
at the community and population levels, associated with improved 
disease prevention and reduced costs for medical care. The impact of 
these paradigms must extend beyond individual communities, to translate 
the maximum benefits of scientific and medical innovation to populations 
at large. In this context, the public health model of care evolves into the 
social health model, which focuses on improving the health of 
populations by reforming suboptimal social structures enabling adequate 
distribution of the products of scientific innovation to those global 
populations in greatest need.8,9  
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